Financial Results for March 31, 2013 (Audited)
Venus Remedies Ltd has informed BSE about the Financial Results for the period ended March 31, 2013.20-05-2013
20-05-2013
Board Meeting on May 18, 2013
With reference to the earlier announcement dated May 09, 2013, regarding Board Meeting on May 18, 2013, Venus Remedies Ltd has now informed BSE that the following agenda item shall also be considered in the above said Proposed meeting :- to consider raising of funds by way of equity/convertible instruments etc.13-05-2013
Board to consider Dividend
Venus Remedies Ltd has informed BSE that a meeting of the Board of Directors of the Company will be held on May 18, 2013, inter alia, to consider and approve :1. Audited Financial Results for the quarter ended March 31, 2013.2. Annual Audited Accounts of the Company for the year ended March 31, 2013.3. Recommendation of dividend for the year 2012-2013.09-05-2013
ELORES awarded Gold Medal for being the best Innovation of 2013
Venus Remedies Ltd has informed BSE regarding "ELORES awarded Gold Medal for being the best Innovation of 2013"06-05-2013
Venus Outlicensed Elores a novel Antibiotic Adjuvant Entity for South Korea after Patent Grant
Venus Remedies Ltd has informed BSE regarding "Venus Outlicensed Elores a novel Antibiotic Adjuvant Entity for South Korea after Patent Grant".02-05-2013
Outcome of Board Meeting
Venus Remedies Ltd has informed BSE that the Board of Directors at its meeting held on March 30, 2013, inter alia, have approved allotment of 8,00,000 equity shares of Rs. 10 each to promoter group Company pursuant to conversion of warrants fully convertible into equity shares.01-04-2013
Venus launches its first OTC product 'Ezenus'
Venus Remedies Ltd has informed BSE regarding "Venus launches its first OTC product 'Ezenus'"25-03-2013
Venus Remedies' MEROPENEM receives market authorization in Mexico
Venus Remedies Ltd has informed BSE regarding "Venus Remedies' MEROPENEM receives market authorization in Mexico"11-03-2013
Venus sign Exclusive Marketing Rights deal for its novel Antibiotic Ajuvant Entity to South Africas second largest Pharmaceutical Company - Adcock
Venus Remedies Ltd has informed BSE regarding "Venus sign Exclusive Marketing Rights deal for its novel Antibiotic Ajuvant Entity to South Africas second largest Pharmaceutical Company - Adcock".25-02-2013